List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1479938/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hospital admissions to geriatric ward related to adverse drug events: a cross-sectional study from the Czech Republic. International Journal of Clinical Pharmacy, 2021, 43, 1218-1226.	2.1	4
2	Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia. Genes, 2021, 12, 1599.	2.4	2
3	Development of novel liquid chromatography method for clinical monitoring of vitamin B1 metabolites and B6 status in the whole blood. Talanta, 2020, 211, 120702.	5.5	6
4	Genetics of Familial Hypercholesterolemia: New Insights. Frontiers in Genetics, 2020, 11, 574474.	2.3	53
5	The Impact of Glucose-Based or Lipid-Based Total Parenteral Nutrition on the Free Fatty Acids Profile in Critically III Patients. Nutrients, 2020, 12, 1373.	4.1	10
6	Stanovisko výboru ÄŒeské spoleÄnosti pro aterosklerózu k doporuÄenÃm ESC/EAS pro diagnostiku a lé dyslipidemiÃ-z roku 2019. Cor Et Vasa, 2020, 62, 185-197.	Äbu 0.1	6
7	InÂvitro comparison of efficacy of catheter locks in the treatment of catheter related blood stream infection. Clinical Nutrition ESPEN, 2019, 30, 107-112.	1.2	10
8	Changes in cholesterol metabolism during acute upper gastrointestinal bleeding: liver cirrhosis and non cirrhosis compared. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 253-258.	0.6	0
9	THE INFLUENCE OF TOTAL PARENTERAL NUTRITION ONÂTHE METABOLISM OF NON-ESTERIFIED FATTY ACIDS INÂCRITICALLY ILL PATIENTS: ONGOING DATA FROM AÂPROSPECTIVE RANDOMIZED STUDY. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2019, 88, 150-158.	0.5	0
10	Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis, 2018, 277, 355-361.	0.8	21
11	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	27.0	510
12	LDL Apheresis – long-term follow-up in a Czech centre. Atherosclerosis, 2017, 263, e150.	0.8	0
13	Plasma NEFA concentration in ICU patients are not related to the fat/glucose based parenteral nutrition regime. Atherosclerosis, 2017, 263, e223.	0.8	0
14	Long-term high carbohydrate parenteral nutrition does not have negative effect on the hepatic function and triglyceridemia. Atherosclerosis, 2017, 263, e223-e224.	0.8	0
15	Impact of lipoprotein apheresis on the content of alpha-tocopherol in cell membranes and lipid peroxidation. Atherosclerosis, 2017, 263, e244.	0.8	0
16	Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis. Atherosclerosis Supplements, 2017, 30, 128-134.	1.2	11
17	Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis. Atherosclerosis Supplements, 2017, 30, 159-165.	1.2	12
18	Lipoprotein Apheresis in the Treatment of Dyslipidemia – the Czech Republic Experience. Physiological Research, 2017, 66, S91-S100.	0.9	7

#	Article	IF	CITATIONS
19	Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project. Physiological Research, 2017, 66, S1-S9.	0.9	21
20	Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis. Journal of Ophthalmology, 2015, 2015, 1-7.	1.3	8
21	Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atherosclerosis Supplements, 2015, 18, 140-145.	1.2	7
22	Pregnancy in homozygous familial hypercholesterolemia – Importance of LDL-apheresis. Atherosclerosis Supplements, 2015, 18, 134-139.	1.2	20
23	Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutrition and Diabetes, 2015, 5, e183-e183.	3.2	38
24	Lipoprotein-Associated Phospholipase A _{2} Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2014, 2014, 1-6.	2.3	10
25	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. Cor Et Vasa, 2014, 56, e133-e139.	0.1	7
26	Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atherosclerosis Supplements, 2013, 14, 179-184.	1.2	22
27	Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of ageâ $\epsilon_{\mathbf{f}}$ elated macular degeneration 2.5â ϵ_{f} years after rheohemapheresis. Acta Ophthalmologica, 2013, 91, e406-8.	1.1	10
28	The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination. Atherosclerosis Supplements, 2013, 14, 77-81.	1.2	7
29	Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration. Journal of Ophthalmology, 2013, 2013, 1-8.	1.3	8
30	Cholesterol metabolism in acute upper gastrointestinal bleeding, preliminary observations. Wiener Klinische Wochenschrift, 2012, 124, 815-821.	1.9	5
31	The importance of rheological parameters in the therapy of the dry form of age-related macular degeneration with rheohaemapheresis. Clinical Hemorheology and Microcirculation, 2012, 50, 245-255.	1.7	6
32	Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: A series of four cases. Journal of Clinical Apheresis, 2012, 27, 215-220.	1.3	35
33	Effects of body fat reduction on plasma adipocyte fatty acid-binding protein concentration in obese patients with type 1 diabetes mellitus. Neuroendocrinology Letters, 2012, 33 Suppl 2, 6-12.	0.2	1
34	Experience with extracorporeal elimination therapy in myasthenia gravis. Transfusion and Apheresis Science, 2011, 45, 251-256.	1.0	5
35	Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmologica, 2011, 89, 463-471.	1.1	19
36	Use of Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry to Demonstrate Decreased Serum Statin Levels after Extracorporeal LDL-Cholesterol Elimination. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	4

#	Article	IF	CITATIONS
37	Plasma albumin levels correlate with decreased microcirculation and the development of skin defects in hemodialyzed patients. Nutrition, 2010, 26, 880-885.	2.4	24
38	Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	5
39	Anti-inflammatory Properties of High-density Lipoprotein Cholesterol in Chronic Hemodialysis Patients: Impact of Intervention. , 2010, 20, 368-376.		3
40	Evaluation of Skin Microcirculation during Hemodialysis. Renal Failure, 2010, 32, 21-26.	2.1	13
41	The importance of rheological parameters in the therapy of microcirculatory disorders. Clinical Hemorheology and Microcirculation, 2009, 42, 37-46.	1.7	28
42	Cholesterol metabolism in active Crohn's disease. Wiener Klinische Wochenschrift, 2009, 121, 270-5.	1.9	24
43	Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2093-2103.	2.3	54
44	Cascade Filtration in the Therapy of the Dry Form of Age-related Macular Degeneration. Therapeutic Apheresis and Dialysis, 2009, 13, 453-454.	0.9	3
45	Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clinical Biochemistry, 2009, 42, 996-1000.	1.9	10
46	Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atherosclerosis Supplements, 2009, 10, 17-20.	1.2	8
47	MALNUTRITION, INFLAMMATION, ATHEROSCLEROSIS AND CALCIFICATION (MIAC SYNDROME) NEGATIVELY INFLUENCE PERIPHERAL BLOOD FLOW DURING HEMODIALYSIS (HD). Atherosclerosis Supplements, 2008, 9, 159.	1.2	0
48	OUTCOME COMPARISON TO TAKE ADVANTAGE OF MODIFIED PLATELETS AGGREGATION AND PFA-100 ANALYSIS TO RATIONALIZE THERAPEUTIC LDL-APHERESIS PROCEDURE. Atherosclerosis Supplements, 2008, 9, 168-169.	1.2	0
49	DETERMINATION OF STATINS IN BIOLOGICAL MATERIALS. Atherosclerosis Supplements, 2008, 9, 204.	1.2	0
50	Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis, 2008, 197, 264-270.	0.8	36
51	Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: A prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure. Hematology, 2007, 12, 571-576.	1.5	3
52	Optimization of therapeutic procedure during LDL-apheresis – verification of the computerized model in clinical practice. Transfusion and Apheresis Science, 2007, 36, 39-45.	1.0	2
53	PO3-65 DECREASED ATHEROGENIC LIPOPROTEINS LINKED TO AGE RELATED MACULAR DEGENERATION (ARD): IMPACT OF HAEMORHEOPHERESIS. Atherosclerosis Supplements, 2007, 8, 34.	1.2	0
54	Safety and Tolerability of Long Lasting LDL-apheresis in Familial Hyperlipoproteinemia. Therapeutic Apheresis and Dialysis, 2007, 11, 9-15.	0.9	23

#	Article	IF	CITATIONS
55	Potential uses of assessment of functional changes in primary hemostasis by the PFA-100 analyzer and modified assessment of platelet aggregation in rationalizing management of patients with familiar hypercholesterolemia treated by extracorporeal LDL-cholesterol elimination. Cor Et Vasa, 2007, 49, 303-311.	0.1	0
56	Th-P16:317 Performance of LDL-apheresis and its relation to haemostasis. Atherosclerosis Supplements, 2006, 7, 563.	1.2	0
57	Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: Relationship to cholesterol turnover. Pharmacological Research, 2006, 54, 421-428.	7.1	28
58	Lipid metabolism in active Crohn's disease: Pre-results. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2006, 150, 363-366.	0.6	3
59	Polyunsaturated Fatty Acids, Phytosterols and Cholesterol Metabolism in the Mediterranean Diet. Acta Medica (Hradec Kralove), 2006, 49, 23-26.	0.5	2
60	W16-P-008 Assessment of absorber efficacy during LDL-apheresis. Atherosclerosis Supplements, 2005, 6, 102.	1.2	0
61	W16-P-009 Relation of carotid intima-media thickness and lipoperoxidation during long-term aggressive lipid lowering with LDL apheresis. Atherosclerosis Supplements, 2005, 6, 102.	1.2	0
62	W16-P-053 Computer aided optimization and standardization of the procedures in lipid lowering immunotherapy. Atherosclerosis Supplements, 2005, 6, 114.	1.2	1
63	W16-P-089 Extracorporal plasmapheresis in the treatment of severe hyperlipidaemia in patient with polymyositis. Atherosclerosis Supplements, 2005, 6, 123.	1.2	0
64	T07-P-002 LDL-lowering immunoapheresis is well tolerated and safe procedure in familial hyperlipoproteinaemia. Atherosclerosis Supplements, 2005, 6, 171.	1.2	0
65	Optimization of the therapeutic procedure during LDL-apheresis—a computerized model. Transfusion and Apheresis Science, 2005, 32, 149-156.	1.0	3
66	Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacological Research, 2005, 51, 31-36.	7.1	11
67	Urinary Neopterin and Microalbuminuria in Patients Treated by Low-density Lipoprotein Apheresis. Pteridines, 2005, 16, 174-183.	0.5	16
68	Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia. Transfusion and Apheresis Science, 2004, 30, 83-87.	1.0	10
69	Development and validation of HPLC method for the determination of α-tocopherol in human erythrocytes for clinical applications. Analytical and Bioanalytical Chemistry, 2003, 376, 444-447.	3.7	11
70	Fluorometric assay of lipoperoxides and chromatographic analysis of \$alpha;-tocopherol and fatty acids as biomarkers of risk from coronary atherosclerosis. Talanta, 2003, 60, 505-513.	5.5	2
71	Fluorimetric determination of the levels of urinary neopterin and serum thiobarbituric acid reactive substances in the nonagenarians. Talanta, 2003, 60, 459-465.	5.5	5
72	Interrelationship between fatty acid composition, lipid peroxidation and alpha-tocopherol consumption post-LDL-apheresis treatment evaluated by liquid chromatography and gas chromatography. Analytica Chimica Acta, 2002, 467, 125-132.	5.4	3

#	Article	IF	CITATIONS
73	Analysis of Fatty Acid, and Lipoprotein, Metabolism by GC and HPLC: Effect of Low-Density Lipoprotein Apheresis. Mikrochimica Acta, 2001, 136, 23-29.	5.0	2
74	Bioanalysis of age-related changes of lipid metabolism in nonagenarians. Journal of Pharmaceutical and Biomedical Analysis, 2001, 24, 1157-1162.	2.8	8
75	Biochemical profile and survival in nonagenarians. Clinical Biochemistry, 2001, 34, 563-569.	1.9	64
76	Dopamine and serotonin VMN release is related to feeding status in obese and lean Zucker rats. NeuroReport, 2000, 11, 2069-2072.	1.2	54
77	The antibiotic resistance survey: a preliminary report on the drug utilization evaluation study at the University Teaching Hospital, Charles University, Czech Republic. Pharmacoepidemiology and Drug Safety, 2000, 9, 237-243.	1.9	3
78	Bioanalysis of PUFA metabolism and lipid peroxidation in coronary atherosclerosis. Journal of Pharmaceutical and Biomedical Analysis, 2000, 22, 563-572.	2.8	8
79	Use of orchiectomy and testosterone replacement to explore meal number-to-meal size relationship in male rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R1366-R1373.	1.8	36
80	Interleukin-1α Injection Into Ventromedial Hypothalamic Nucleus of Normal Rats Depresses Food Intake and Increases Release of Dopamine and Serotonin. Pharmacology Biochemistry and Behavior, 1999, 62, 61-65.	2.9	46
81	Infusion of Nicotine Into the LHA Enhances Dopamine And 5-HT Release and Suppresses Food Intake. Pharmacology Biochemistry and Behavior, 1999, 64, 155-159.	2.9	51
82	Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiology and Behavior, 1999, 68, 99-107.	2.1	57
83	Fatty acids content of cell membranes and plasma lipoproteins during LDL-apheresis. Atherosclerosis, 1999, 144, 189.	0.8	0
84	Potential Strategies for Ameliorating Early Cancer Anorexia. Journal of Surgical Research, 1999, 81, 69-76.	1.6	12
85	Distribution of fenofibric acid in lipoprotein fractions of patients. European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23, 287-294.	1.6	2
86	Systemic Nicotine Administration Suppresses Food Intake Via Reduced Meal Sizes in Both Male and Female Rats. Acta Medica (Hradec Kralove), 1998, 41, 167-173.	0.5	27
87	3.P.8 Antioxidant status and vitamin E in lipoprotein fractions during hypolipidemic therapy. Atherosclerosis, 1997, 134, 200.	0.8	Ο
88	4.P.64 Serum lipoproteins lowering and diabetic exudative retinopathy. Atherosclerosis, 1997, 134, 309.	0.8	1
89	Hypercaloric lipid and glucose infusion reduces the mitochondrial respiratory activity in the regenerating rat liver. Clinical Nutrition, 1994, 13, 368-373.	5.0	2
90	Liver regeneration in partially hepatectomized rats infused with carnitine and lipids. Experimental and Toxicologic Pathology, 1992, 44, 165-168.	2.1	17

6